Providence Health & Services
Clinical trials sponsored by Providence Health & Services, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Supercharged immune cells take on incurable tumors Results expected Dec 2026 (estimated)
- New combo therapy aims to shrink head and neck tumors before surgery Results expected Jan 2027 (estimated)
- Custom-Made immune cells take on incurable tumors Results expected Apr 2027 (estimated)
- Experimental drug combo aims to shrink aggressive breast tumors before surgery Results expected Jun 2027 (estimated)
-
Experimental drug combo aims to shrink aggressive breast tumors before surgery
Disease control Recruiting nowThis phase II trial tests whether adding an experimental drug called INBRX-106 to the immunotherapy pembrolizumab (Keytruda) can shrink tumors in people with stage II or III triple-negative breast cancer before they receive standard chemotherapy. The study will enroll 12 adults w…
Phase 2 • Sponsor: Providence Health & Services • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a new antibody help the immune system fight advanced cancers?
Disease control Recruiting nowThis early-phase trial is testing an experimental drug called M3T01, a monoclonal antibody that targets a protein called FasL, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study aims to see if M3T01 is safe and tolerable when given al…
Phase 1 • Sponsor: Providence Health & Services • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Supercharged t cells take on Hard-to-Treat cancers
Disease control Expanded accessThis treatment program tests a personalized cell therapy for people with advanced pancreatic or colorectal cancers that have a specific genetic mutation (KRAS G12D). Patients' own immune cells are collected, genetically engineered to recognize and attack the cancer, and then infu…
Sponsor: Providence Health & Services • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC